EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 8, 2014, Pages 1967-1978

  Wang, Shuai ^a   Wang, Zhou ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Clinicopathological features; EGFR; Mainland China; Mutation analysis; Non small cell lung cancer; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADENOCARCINOMA; ARTICLE; CHINA; DISEASE ASSOCIATION; DRUG SENSITIVITY; EXON; GENE DELETION; GENE INSERTION; GENE MUTATION; HISTOLOGY; HUMAN; META ANALYSIS; MUTATION RATE; NON SMALL CELL LUNG CANCER; PUBLISHING; SCREENING; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING;

EID: 84907214207     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Nicholson RI, Gee JM and Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-S15.
3. Scaltriti M and Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
4. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, Gazdar AF and Fujisawa T. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 2005; 36: 1127-1134.
5. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
7. Mitsudomi T and Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-1824.
8. Sharma SV, Bell DW, Settleman J and Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
10. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre stu-dy (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
11. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A and Wistuba I. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006; 1: 231-239.
12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
13. Tanaka T, Matsuoka M, Sutani A, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010; 126: 651-655.
14. Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T, Han Y, Huang L, Zhu Y, Li X and Yan X. EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features. Int J Mol Sci 2013; 14: 24549-24559.
15. Wu Y, Lin J and Wang K. EGFR mutations in lung cancers and sensitivity to gefitinib in Chinese (Abstract). J Clin Oncol 2005; 23: 7089.
16. Liu Y, Wu BQ, Zhong HH, Hui P and Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. Int J Clin Exp Pathol 2013; 6: 1880-1889.
17. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD and Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
18. Guo J, Zhou C, Zhang J and Tang L. Relationship between mutations of epidermal growth factor receptor in the plasma and pleural effusion and responses to gefitinib in advanced pretreated non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2007; 10: 504-507.
19. Li Z, Zhang LJ, Wang WP, Guo K, Shao JY and Rong TH. Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2011; 33: 666-670.
20. Han Y, Xu JM, Duan HQ, Song ST, Liu XQ, Zhang Y and Zhang JS. EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2007; 29: 278-283.
21. Lau J, Ioannidis JP and Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
22. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Qin BM, Chen X, Zhu JD and Pei DQ. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res 2005; 15: 212-217.
24. Xu J, He J, Yang H, Luo X, Liang Z, Chen J, Cai Z, Xu J and Ren-Heidenreich L. Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark 2011-2012; 10: 63-69.
25. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS and Wu YL. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012; 7: e40109.
26. Li Y, Li Y, Wang T, Wei S, Wang J, Wong M, Wang Y, Zhou Q, Liu H and Chen J. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 2013; 8: e52093.
27. Jing CW, Wang Z, Cao HX, Ma R and Wu JZ. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev 2013; 14: 6619-6623.
28. Zhang Y, Wang Q, Han ZG and Shan L. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. Asian Pac J Cancer Prev 2013; 14: 2879-2883.
29. Zhang J, Liang ZY, Zeng X, Wu SF, Gao J and Liu TH. Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancers by real-time polymerase chain reaction using scorpion amplification refractory mutation system. Zhonghua Bing Li Xue Za Zhi 2008; 37: 294-299.
30. Liang ZY, Zeng X, Zhang J, Wu SF, Gao J and Liu TH. Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma. Zhonghua Bing Li Xue Za Zhi 2008; 37: 654-659.
31. Yin XW, Jiang XT, Yuan YT and Du YP. Influence of mutations in epidermal growth factor receptor gene on growth, metastasis and survival rate of non-small cell lung carcinoma. Zhonghua Yi Xue Za Zhi 2010; 90: 1808-1812.
32. Feng Q, Li XH, Chen Z, He JS, Wang CX, Zhou LX and Xue WC. Epidermal growth factor receptor gene mutations and clinicopathologic correlation in 309 patients with non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi 2011; 40: 660-663.
33. Sun MH, Yang F, Shen L, Zhang L, Chen Y, Cai X, Zhu XL and Zhou XY. Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types. Zhonghua Bing Li Xue Za Zhi 2011; 40: 655-659.
34. Zhang J, Wu J, Gao H, Zhu L, Shao JC, Shi MP and Han BH. Epidermal growth factor receptor gene mutations, amplification and clinicopathologic correlation in patients with lung cancer. Zhonghua Bing Li Xue Za Zhi 2011; 40: 675-678.
35. Wang LS, Zhang Y, Lu XJ, Lu HJ, Zhou L, Wang YS, Deng L, Huang MJ, Peng F, Wang J, Ren L, Hou M, Li L, Xu Y, Ying BW and Lu Y. Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancer using bi-loop probe specific primer quantitative PCR. Zhonghua Bing Li Xue Za Zhi 2011; 40: 667-670.
36. Gao J, Chen JQ, Zhang L and Liang ZY. Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system. Zhonghua Bing Li Xue Za Zhi 2012; 41: 652-656.
37. Sun LN, Luan HL, Zang FL, Wang M, Dong N, Guo Y, Sun BC and Zhan ZL. Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2010; 32: 667-670.
38. Zhang XT, Li LY and Chang XY. Efficacy and correlation with predictive markers of gefitinib in pretreated Chinese patients with advanced NSCLC (Abstract). J Clin Oncol 2005; 23: 7240.
39. Zhang L, Zhang X and Wang X. The status of epidermal growth factor receptor (EGFR) mutations at exon 19 and 21 in Chinese patients with NSCLC (Abstract). J Clin Oncol 2005; 23: 7097.
40. Zhou C. Epidermal growth factor receptor mutations in Chinese patients with non-small cell lung cancer (Abstract). J Clin Oncol 2005; 23: 7101.
41. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ and Kim NK. Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-2501.
42. Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY and Yang PC. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008; 178: 847-853.
43. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15: 2076-2084.
44. Chan SK, Gullick WJ and Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer 2006; 42: 17-23.
45. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
46. Wang SY, Hu YL, Wu YL, Li X, Chi GB, Chen Y and Dai WS. A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996; 14: S99-S105.
47. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B and Rusch VW. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24: 1700-1704.